Stefania Nobili*, Daniele Lavacchi†, Gabriele Perrone*, Giulio Vicini†, Renato Tassi‡1, Ida Landini*,
AnnaMaria Grosso§, Giandomenico Roviello*¶, Roberto Mazzanti‡, Carmine Santomaggio¶2, Enrico Mini*¶
Oncology Research, Vol.28, No.3, pp. 237-248, 2020, DOI:10.3727/096504019X15755437099308
Abstract The use of vinorelbine as a single agent or in combination regimens in non-small cell lung cancer (NSCLC) is
associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectable or metastatic NSCLC patients, according to real-world treatment patterns, has
still not been widely explored. Eighty-one patients treated at a single institution were retrospectively analyzed.
Thirty-seven received standard first-line single-agent vinorelbine, and 44 received vinorelbine plus platinum
drugs, based on physician’s choice; 61.7% were older than 70 years, and 60.5% were affected by 2 comorbidities. Sixty-three patients were evaluable for… More >
Login
Register
